Company intelligence / Profile preview

Cypris Therapeutics

Syracuse, New York, United Statescypristx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cypris Therapeutics has developed a proprietary synthetic chemistry platform enabling the creation of novel small molecule therapies inspired by nature. Their lead program targeting glioblastoma demonstrated 60% greater effectiveness than current options with minimal toxicity in preclinical studies. The company is also expanding its pipeline to address pancreatic and colon cancers

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Partnerships

Ichor Life SciencesFlorida State University

Beyond the preview

Go deeper on Cypris Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cypris Therapeutics.

Explore the full profile